References
- Masters C, Beyreuther K. Alzheimer’s centennial legacy: prospects for rational therapeutic intervention targeting the Aβ amyloid pathway. Brain129(Pt 11), 2823–2839 (2006).
- Evin G, Sernee MF, Masters CL. Inhibition of γ-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies. CNS Drugs20, 351–372 (2006).
- Iwatsubo T. The γ-secretase complex: machinery for intramembrane proteolysis. Curr. Opin. Neurobiol.14(3), 379–383 (2004).
- Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and γ-secretase activity. Nature398(6727), 513–517 (1999).
- Lazarov V, Fraering PC, Ye W, Wolfe MS, Selkoe DJ, Li H. Electron microscopic structure of purified, active γ-secretase reveals an aqueous intramembrane chamber and two pores. Proc. Natl Acad. Sci. USA103(18), 6889–6894 (2006).
- Sato C, Morohashi Y, Tomita T, Iwatsubo T. Structure of the catalytic pore of γ-secretase probed by the accessibility of substituted cysteines. J. Neurosci.26, 12081–12088 (2006).
- De Strooper B, Annaert W, Cupers P et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain. Nature398, 518–522 (1999).
- Lim G, Yang F, Chu, T et al. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer’s disease. J. Neurosci.20, 5709–5714 (2000).
- Weggen S, Eriksen JL, Das P et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature414, 212–216 (2001).
- Beher D, Clarke EE, Wrigley JD et al. Selected non-steroidal anti-inflammatory drugs and their derivatives target γ-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem.279, 43419–43426 (2004).
- Lleo A, Berezovska O, Herl L et al. Nonsteroidal anti-inflammatory drugs lower Aβ42 and change presenilin 1 conformation. Nat. Med.10, 1065–1066 (2004).
- Eriksen JL, Sagi SA, Smith TE et al. NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42in vivo. J. Clin. Invest.112, 440–449 (2003).
- Kukar T, Prescott S, Eriksen JL et al. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci.8, 54 (2007).
- Kukar T, Murphy MP, Eriksen JL et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Aβ42 production. Nat. Med.11, 545–550 (2005).
- Kukar TL, Ladd TB, Bann MA et al. Substrate-targeting γ-secretase modulators. Nature453, 925–929 (2008).
- Ren Z, Schenk D, Basi GS, Shapiro IP. Amyloid-protein precursor juxtamembrane domain regulates specificity of γ-secretase-dependent cleavages. J. Biol. Chem.282, 35350–35360 (2007).
- Thinakaran G, Koo E. γ trafficking, processing and function. J. Biol. Chem. (2008) (Epub ahead of print).
- Wilcock G, Black S, Hendrix S et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer’s disease: a randomised Phase II trial. Lancet Neurol.7, 483–493 (2008).
- Osenkowski P, Ye W, Wang R, Wolfe MS, Selkoe DJ. Direct and potent regulation of γ-secretase by its lipid microenvironment. J. Biol. Chem.283, 22529–22540 (2008).
- Gamerdinger M, Clement A, Behl C. Effects of sulindac sulfide on the membrane architecture and the activity of γ-secretase. Neuropharmacology254, 998–1005 (2008).
- Chen F, Hasegawa H, Schmitt-Ulms G et al. TMP21 is a presenilin complex component that modulates γ-secretase but not ε-secretase activity. Nature440, 1208–1212 (2006).
- Serneels L, Van Biervliet J, Craessaerts K et al. Aph1b γ-secretase generates long Aβ peptides and genetic ablation improves Alzheimer's disease phenotypes without affecting notch signaling in the mouse. Alzheimer’s and dementia4(Suppl. 2), T136 (2008) (Abstract 9O2-03-04).
Websites
- Fagan T. Merck withdraws Vioxx. 30 September 2004 www.alzforum.org/new/detailprint.asp?id=1083 (Accessed 20 August 2008)
- Alzheimer Association. Four Alzheimer’s clinical trials address a variety of treatment targets - amyloid, tau, synapse formation. July 29 2008 www.alz.org/icad/_release_icad_072908_130pm_trials.asp (Accessed 20 August 2008)